While accumulating data have shown a survival benefit for adding a CDK4/6 inhibitor to ET in endocrine-resistant disease, no clinical trial has been performed comparing this class of drugs versus therapies targeting the PI3K/Akt/mTOR pathway, including PI3K inhibitors, when associated with ET. Here, PIK3CG is linked to essential thrombocythemia.